AGP Executive Report
Last update: 10 hours agoPublic Health: Switzerland reported 544 tuberculosis infections in 2025, the highest level since 2018, with the rise driven almost entirely by people born abroad—especially teenagers and young adults—while the overall reporting rate climbed to 6.0 per 100,000 (still below the European average of 8.4). Cancer Care (EU/Liechtenstein): The EMA’s CHMP issued positive opinions for new perioperative bladder cancer options: Merck’s KEYTRUDA (pembrolizumab) plus PADCEV (enfortumab vedotin) for resectable muscle-invasive bladder cancer, and an expanded use pathway for cisplatin-eligible and ineligible patients, with a final European Commission decision expected in Q4 2026 (including Liechtenstein). Metabolic/Intestinal Health: Zealand Pharma received a positive CHMP opinion for Zeydovio (glepaglutide) for adults with short bowel syndrome, aiming to reduce weekly parenteral support and help some patients wean off entirely. Liechtenstein Politics & Health Rights: Liechtenstein’s Catholic prince Alois vowed to oppose the newly approved 12-week abortion time-limit regime after Parliament voted 13–12.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
